Source comparison
CJC-1295 Cause Any Side Effects in Studies: Comparison Across Peptide Classes
CJC-1295 DAC Injection-site reactions, transient flushing 15–30 Mast cell histamine release; NO-mediated vasodilation 48–96 hours Well-tolerated GHS with predictable, self-limiting effects. Superior safety profile vs exogenous GH Ipamorelin Injection-site reac
This comparison does not assign a generated winner or score.
- CJC-1295 DAC
- Injection-site reactions, transient flushing
- 15–30
- Mast cell histamine release; NO-mediated vasodilation
- 48–96 hours
- Well-tolerated GHS with predictable, self-limiting effects. Superior safety profile vs exogenous GH
- Ipamorelin
- Injection-site reactions, transient hunger increase
- 10–18
- Ghrelin receptor agonism increases gastric motility
- 24–48 hours
- Minimal systemic effects; hunger spike may interfere with caloric restriction protocols
- Sermorelin
- Injection-site reactions, flushing, nausea
- 20–35
- Short half-life requires multiple daily dosing; GI effects from rapid GH pulse
- 12–24 hours
- Higher AE frequency than CJC-1295 due to dosing frequency. Reconstitution errors more common
- MOD-GRF (1-29)
- Injection-site reactions, headache
- 12–22
- Rapid GH pulse without DAC stability; sharper peak-to-trough
- Shorter half-life reduces cumulative exposure but increases injection frequency burden